论文部分内容阅读
慢性髓系细胞白血病(chronic myeloid leukemia,CML)是一种以出现t(9;22)特征性染色体核型改变导致骨髓造血干细胞克隆性增殖的血液系统恶性肿瘤。随着第一代酪氨酸激酶抑制剂(TKI)甲磺酸伊马替尼的问世及广泛应用,慢性期CML的疗效与预后已大为改观,作为一线治疗的异基因造血干细胞移植已经被TKI所取代。然而,被认为属终末期的急变期CML(CML-BP),预
Chronic myeloid leukemia (CML) is a hematologic malignancy that causes clonal multiplication of bone marrow hematopoietic stem cells in the presence of t (9; 22) characteristic karyotype changes. With the advent and widespread use of the first generation tyrosine kinase inhibitor (TKI) imatinib mesylate, the efficacy and prognosis of chronic phase CML have dramatically improved. Allogeneic hematopoietic stem cell transplantation as first-line therapy has been TKI replaced. However, CML (CML-BP), which is considered to be terminal stage, pre-date